42202-95-9

Basic information

• Product Name: ALPHA-CHLORO-4-FLUOROBENZALDOXIME
• Synonyms: ALPHA-CHLORO-4-FLUOROBENZALDOXIME;Benzenecarboximidoyl chloride, 4-fluoro-N-hydroxy-;4-Fluoro-N-hydroxybenzimidoyl chloride;4-fluoro-N-hydroxy-Benzenecarboximidoyl chloride
• CAS NO: 42202-95-9
• Molecular Formula: C₇H₅ClFNO
• Molecular Weight: 173.57
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
• Mol File: 42202-95-9.mol
• Article Data: 90

Chemical Properties

• Boiling Point: 269.5 °C at 760 mmHg
• Flash Point: 116.8 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 0.00357mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: ALPHA-CHLORO-4-FLUOROBENZALDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: ALPHA-CHLORO-4-FLUOROBENZALDOXIME(42202-95-9)
• EPA Substance Registry System: ALPHA-CHLORO-4-FLUOROBENZALDOXIME(42202-95-9)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 42202-95-9(Hazardous Substances Data)

Usage

General Description

ALPHA-CHLORO-4-FLUOROBENZALDOXIME is a chemical compound with the molecular formula C7H5ClFNO. It is a pale yellow solid that is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. ALPHA-CHLORO-4-FLUOROBENZALDOXIME is also known for its reactivity as an oxime, meaning it has a nitrogen-oxygen double bond, which makes it useful for chemical reactions. It is important to handle this compound with care as it may present hazards if not properly managed, including potential irritant effects on the skin, eyes, and respiratory system. Overall, ALPHA-CHLORO-4-FLUOROBENZALDOXIME is a versatile chemical compound with multiple applications in various industries.

InChI:InChI=1/C7H5ClFNO/c8-7(10-11)5-1-3-6(9)4-2-5/h1-4,11H

Upstream product

• 459-23-4 (E)-4-fluorobenzaldehyde oxime 
• 459-57-4 4-fluorobenzaldehyde 
• 459-23-4 4-fluorobenzaldoxime 

Downstream Products

• 1736-21-6 3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 113003-52-4 (3aS,6R,6aR)-6-Ethoxy-3-(4-fluoro-phenyl)-6,6a-dihydro-3aH-furo[3,4-d]isoxazol-4-one 
• 138552-54-2 3-(4-fluorophenyl)-5-(1,2-O-isopropylidene-α-D-xylo-tetrafuranos-4-yl)-2-isoxazoline 
• 138552-54-2 (3aR,5S,6S,6aR)-5-[(S)-3-(4-Fluoro-phenyl)-4,5-dihydro-isoxazol-5-yl]-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-ol 
• 159693-23-9 5-(Chloro-difluoro-methyl)-3-(4-fluoro-phenyl)-isoxazole-4-carboxylic acid methyl ester 
• 159693-09-1 3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid methyl ester 
• 206055-89-2 3-(4-fluorophenyl)-5-hydroxymethylisoxazole 
• 334930-07-3 3-(4-Fluorophenyl)-isoxazole-4-carboxylic acid 
• 465514-05-0 5-methyl-3-(4-fluoro-phenyl)-isoxazole-4-carboxylic acid chloride 
• 142259-55-0 3,3,3-Trifluor-2-<3-(4-fluorphenyl)isoxazol-5-yl>alanin-methylester 
• 666746-60-7 t-butyl 4-[3-(4-fluorophenyl)-5-trifluoromethyl-1,4,2-dioxazolin-5-yl]-2-methylcarbanilate 
• 112043-74-0 (η5-cyclopentadienyl)(triphenylphosphine)Rh(η2-C(p-FC6H4)NOC(O)) 
• 112022-79-4 (η5-C5-Me5)(PMe3)Rh(η2-C(p-FC6H4)NOC(O)) 

Relevant articles and documents

COMPOUNDS AS CASEIN KINASE INHIBITORS

Provided are novel casein kinase inhibitors, or pharmaceutically acceptable salts thereof. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also provided.

Design and synthesis of sinomenine isoxazole derivatives via 1,3-dipolar cycloaddition reaction

A novel structure of sinomenine isoxazole derivatives is synthesised from sinomenine hydrochloride and aromatic aldehydes and requires six steps. 19 target compounds have been obtained in good yields. The sinomenine hydrochloride transforms to 4-alkynyl sinomenine, which is a key intermediate product to synthesise the target sinomenine isoxazole compounds, after a neutralisation reaction with ammonia and substitution reaction with 3-chloropropyne. Another key intermediate product is 1,3-dipole, which can be obtained from aromatic aldehyde. After treatment with hydroxylamine hydrochloride and then sodium carbonate solution, aromatic aldehyde is converted to aldehyde oxime, which reacts with N-chlorosuccinimide (NCS) to afford aryl hydroximino chloride. 1,3-Dipole is eventually formed in situ while triethylamine (TEA) in DMF is added dropwise. Then 4-alkynyl sinomenine is added to provide the sinomenine isoxazole derivative via 1,3-dipolar cycloaddition reaction as the key step. All the target compounds are characterised by melting point, 1H NMR, 13C NMR, HRMS and FT-IR spectroscopy.

Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors

α-Glucosidase inhibition is a valid approach for controlling hyperglycemia in diabetes. In the current study, new molecules as a hybrid of isoxazole and dibenzazepine scaffolds were designed, based on their literature as antidiabetic agents. For this, a series of dibenzazepine-linked isoxazoles (33–54) was prepared using Nitrile oxide-Alkyne cycloaddition (NOAC) reaction, and evaluated for their α-glucosidase inhibitory activities to explore new hits for treatment of diabetes. Most of the compounds showed potent inhibitory potency against α-glucosidase (EC 3.2.1.20) enzyme (IC50 = 35.62 ± 1.48 to 333.30 ± 1.67 μM) using acarbose as a reference drug (IC50 = 875.75 ± 2.08 μM). Structure-activity relationship, kinetics and molecular docking studies of active isoxazoles were also determined to study enzyme-inhibitor interactions. Compounds 33, 40, 41, 46, 48–50, and 54 showed binding interactions with critical amino acid residues of α-glucosidase enzyme, such as Lys156, Ser157, Asp242, and Gln353.